6 citations
,
July 2024 in “Heliyon” Steroid 5α-reductase evolved from protists and diversified in eukaryotes, with specific roles in mammals and plants.
4 citations
,
December 2024 in “European Journal of Medicinal Chemistry” New pyrazole-based inhibitors show promise for treating metabolic diseases and other conditions.
4 citations
,
March 2022 in “Pharmaceutics” Regenerative cellular therapies show promise for treating non-scarring hair loss but need more research.
3 citations
,
April 2023 in “Cytotechnology” 3 citations
,
May 2016 in “Dermatopathology” Lrig1 could be a marker for advanced sebaceous carcinoma.
2 citations
,
September 2025 in “Frontiers in Endocrinology” SARMs show promise but need more evidence to prove they're better than traditional androgens.
2 citations
,
March 2021 in “Reproduction” Finasteride may affect male fertility by interfering with specific sperm signaling.
1 citations
,
October 2025 in “Transfusion Medicine and Hemotherapy” Platelet-rich plasma shows promise for treating dry eye disease, but more standardized trials are needed.
1 citations
,
July 2007 in “Journal of Investigative Dermatology” The mutation causes hairless mice due to mislocalized and dysfunctional HR protein.
1 citations
,
November 2005 in “Journal of Andrology” The meeting highlighted promising genetic treatments for male fertility issues but noted concerns about certain cancer risks and ICSI safety.
April 2026 in “Metabolites” Chronic skin diseases and metabolic syndrome are linked by shared inflammation pathways.
February 2026 in “International Journal of Molecular Sciences” Extracellular vesicles show promise for medical use but face challenges in standardization and safety.
November 2025 in “BMC Urology” Larger prostate size, longer surgery, and smoking increase risks, while finasteride and experienced surgeons reduce them during prostate surgery.
November 2025 in “Cancers” Men with male pattern baldness may have a slightly higher risk of prostate cancer.
January 2025 in “Biomedical Reports” Telitacicept helped stabilize complement levels in a patient with lupus and thyroid cancer.
January 2025 in “International Journal of Molecular Sciences” Psoriasis involves immune and genetic factors, and understanding these can improve treatments.
November 2024 in “Forensic Sciences” Understanding the Y chromosome is key to male health, aging, and developing diagnostic tools.
November 2024 in “Applied Sciences” Wild strawberry waste extract can be a sustainable cosmetic ingredient for treating acne and hair loss.
August 2024 in “Aesthetic Plastic Surgery” Exosome treatment safely increases hair density in male patients with androgenetic alopecia.
September 2023 in “Cureus” Topical finasteride might be a good alternative for hair loss treatment with fewer side effects, but more research is needed.
March 2014 in “Hair transplant forum international” Hair transplant surgeons should also focus on their patients' overall health, including regular check-ups and screening for common health issues.
March 2003 in “Oncology Times” Further research is needed to develop effective cancer prevention strategies.
154 citations
,
March 2012 in “Indian Journal of Surgical Oncology” PSA is best for detecting prostate cancer recurrence and evaluating treatment response.
41 citations
,
June 1999 in “The Prostate” Finasteride reduces PSA levels, terazosin doesn't affect them, and tracking prostate cancer in patients taking finasteride could be difficult.
5 citations
,
January 2010 in “Acta Chirurgica Iugoslavica” Higher urethral PSA levels after prostate removal may be linked to more scalp hair loss and more PSA in urethral glands.
3 citations
,
June 1999 in “The Prostate” Finasteride reduces PSA levels, terazosin doesn't affect them, and tracking prostate cancer in patients taking finasteride could be difficult.
1 citations
,
September 2025 in “Archivio Italiano di Urologia e Andrologia” Serenoa repens extract, alone or with other supplements, improves urinary symptoms and lowers PSA levels.
1 citations
,
June 2007 in “Journal of Clinical Oncology” Weekly bicalutamide is safe and effective, with 50 mg/week recommended.
April 2012 in “The Journal of Urology” Finasteride therapy reduces PSA levels and prostate size, helping diagnose prostate cancer.
November 2007 in “Cancer Epidemiology and Prevention Biomarkers” Higher C-peptide levels in African-American men and higher HbA1c levels in Caucasian men are linked to lower PSA levels.